Norepinephrine seemed to be a safer vasopressor than epinephrine for patients with cardiogenic shock following acute myocardial infarction, according to a small randomized trial conducted in France. Significantly more patients given epinephrine developed refractory cardiogenic shock, causing the study to be stopped early.

New research published in the Journal of the American Medical Association suggests an association between black postmenopausal women who are carriers of apolipoprotein L1 (APOL1) genotypes and hospitalizations for heart failure with preserved ejection fraction (HFpEF). The findings, however, do not support an association between APOL1 genotypes and coronary heart disease, stroke or mortality.

Boston Scientific plans to acquire Cryterion Medical, a company developing a single-shot cryoablation platform to treat patients with atrial fibrillation (AFib). Already an investor in the company, Boston Scientific will purchase the remaining 65 percent stake for $202 million in up-front cash.

A federal investigation into the potential overuse of primary prevention implantable cardioverter defibrillators (ICDs) appears to have made hospitals more judicious in their use of the devices, according to a study published July 3 in the Journal of the American Medical Association.

Learning a heart attack patient has nonobstructive coronary arteries shouldn’t necessarily be met with relief, according to a multicenter study published in the Journal of the American Heart Association.

Human stem cells helped restore left ventricular ejection fraction (LVEF) in monkeys induced with experimental heart failure, giving scientists hope a similar treatment could work in humans following myocardial infarction.

The Face, Arm, Speech and Time (FAST)-based public education, utilized in several countries to improve stroke symptom recognition, has not improved the response to transient ischemic stroke (TIA) and minor stroke in the United Kingdom, according to new research published July 2 in JAMA Neurology.

Nearly all transcatheter heart valves (THVs) leave debris following aortic valve replacement, reinforcing the potential for embolic protection devices to reduce the burden of silent brain infarctions and future strokes.